Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer.

Mohamadou I, Matignon M, Malard S, Lombardi Y, Buob D, Moktefi A, Jamme M, Ouali N, Rafat C, François H, Petit-Hoang C, Rondeau E, Mesnard L, Grimbert P, Taupin JL, Luque Y

Open source

DOI: 10.3389/ti.2023.10844
Published: 2023
Container: Transplant international : official journal of the European Society for Organ Transplantation
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/ti.2023.10844,
  title = {Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer.},
  author = {Mohamadou I and Matignon M and Malard S and Lombardi Y and Buob D and Moktefi A and Jamme M and Ouali N and Rafat C and François H and Petit-Hoang C and Rondeau E and Mesnard L and Grimbert P and Taupin JL and Luque Y},
  year = {2023},
  journal = {Transplant international : official journal of the European Society for Organ Transplantation},
  doi = {10.3389/ti.2023.10844},
  url = {https://doi.org/10.3389/ti.2023.10844}
}

RIS

TY  - JOUR
TI  - Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer.
AU  - Mohamadou I
AU  - Matignon M
AU  - Malard S
AU  - Lombardi Y
AU  - Buob D
AU  - Moktefi A
AU  - Jamme M
AU  - Ouali N
AU  - Rafat C
AU  - François H
AU  - Petit-Hoang C
AU  - Rondeau E
AU  - Mesnard L
AU  - Grimbert P
AU  - Taupin JL
AU  - Luque Y
PY  - 2023
JO  - Transplant international : official journal of the European Society for Organ Transplantation
DO  - 10.3389/ti.2023.10844
UR  - https://doi.org/10.3389/ti.2023.10844
ER  -

APA

I, M., M, M., S, M., Y, L., D, B., A, M., M, J., N, O., C, R., H, F., C, P., E, R., L, M., P, G., JL, T., & Y, L. (2023). Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer.. Transplant international : official journal of the European Society for Organ Transplantation. https://doi.org/10.3389/ti.2023.10844

Source records

pubmed · retrieved 2026-09-27T09:40:20.721Z